MNPR Monopar Therapeutics

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its abstract on camsirubicin submitted to the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting has been selected for a poster presentation. CTOS 2022, held in Vancouver, Canada, brings together the world’s leading sarcoma specialists. Monopar’s poster will be the first formal release of data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma (ASTS) patients.

“We are looking forward to sharing data from our dose-escalating camsirubicin study with leading sarcoma specialists from around the world in a little over a month,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Meeting Details:

Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference

Date: November 16-19, 2022

Location: Vancouver Convention Centre, Vancouver, BC, Canada

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: .

CONTACT:  

Monopar Therapeutics Inc.

Investor Relations  

Kim R. Tsuchimoto  

Chief Financial Officer  

Follow Monopar on social media for updates: 

Twitter:   LinkedIn:

 



EN
12/10/2022

Underlying

MNPRMonopar Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and ...

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline...

November 13, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Presents New Data and Analyses on Rapidly Improved Copper Bala...

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking p...

November 9, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - T...

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from Nov...

October 15, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritt...

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock to certain investors, pr...

September 24, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter t...

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdat...

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch